Sfoglia per Dipartimento DIPARTIMENTO DI FISIOLOGIA E FARMACOLOGIA "VITTORIO ERSPAMER"
Natural and naturally-derived compounds as new chemopreventive agents
2014
Neurodegenerative and neuroinflammatory mechanisms in neurological and psychiatric disorders
2026
Neuroeconomics processes underlying decision-making in joint vs individual actions: a behavioral and EEG study on non-human primates
2021
Neurophysiological mechanisms of quiet vigilance in neurodegenerative diseases: an electroencephalography research program
2020
New strategies leveraging ALIAmides in acute and chronic anti-inflammatory therapies
2025
New therapeutic targets for Parkinson’s disease and comorbid psychiatric disorders
2025
New therapeutic targets for the treatment of Alzheimer’s disease – Novel insight from transgenic models
2020
Novel promising pharmacological targets and drugs for the treatment of neuropathic pain: focusing on prokineticin system and selective A3 adenosine receptor (A3AR) agonists in an animal model
2019
A novel selective cell-permeable peptide disrupts presynaptic JNK2-STX1a interaction, providing neuroprotection and preventing glutamate-mediated excitotoxicity
2018
Oleoylethanolamide in the homeostatic and non-homeostatic control of eating
2019
Peroxidation of leukocytes index ratio and a functional mathematical index: their potential application in screening of non-communicable diseases
2018
Pesticides exposure and premature thelarche: experimental and epidemiological tools for toxicological assessment
2022
Pharmacological characterization of new compounds and herbal derivatives for pain and inflammation treatment
2022
Pharmacological modulation of lipid metabolism as a regulator of cellular plasticity, homeostasis, and stress responses in colon and liver cell models
2026
Pharmacological modulation of the gut microbiota and epithelial barrier: new therapeutic perspectives in obesity
2026
Pre-clinical evaluation of novel pharmacological targets for the treatment of obesity and eating disorders: focus on Oleoylethanolamide and the oxytocinergic system
2024
Preclinical pharmacological characterization of GLP-1 agonists, PPARα activators, and peripheral CB1 antagonists in the treatment of high-fat high-fructose diet–induced metabolic and neuroendocrine dysregulation
2026
Prospects for new drugs to treat aberrant eating patterns: possible role of Oleoylethanolamide
2022
Real-world clinical outcomes in HER2 positive and negative metastatic breast cancer patients treated with Abemaciclib, Ribociclib and Trastuzumab deruxtecan
2025
Resilience and susceptibility to stress-related disorders: insights from animal models
2021
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile